1 research outputs found
Synthesis and Antitumor Efficacy of a β-Glucuronidase-Responsive Albumin-Binding Prodrug of Doxorubicin
In this paper we describe the synthesis and biological
evaluation of the first β-glucuronidase-responsive albumin-binding
prodrug designed for the selective delivery of doxorubicin at the
tumor site. This prodrug leads to superior antitumor efficacy in mice
compared to HMR 1826, a well-known glucuronide prodrug of doxorubicin
that cannot bind covalently to circulating albumin. Furthermore, this
compound inhibits tumor growth in a manner similar to that of doxorubicin
while avoiding side effects induced by the free drug